Evidence-Based Strategies to Facilitate Access to Therapies for Patients with Spinal Muscular Atrophy
Premiere Date: Friday, April 16, 2021This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- ABP (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, April 16, 2022
Note: Credit Is No Longer Available
 | Crystal M. Proud, MD (Moderator) Director, Neuromuscular Clinic and Spinal Muscular Atrophy Center Children's Hospital of the King's Daughters Medical Director CHKD Novel Therapeutics and Gene Therapy Center Norfolk, VA |
 | Erin Neil, DO Clinical Assistant Professor of Pediatrics Director, Pediatric Neuromuscular Program Co-Director, Muscular Dystrophy Association Clinic Michigan Medicine University of Michigan Medical School Medical Director, State of Michigan’s SMA Newborn Screening Program Ann Arbor, MI |
Spinal muscular atrophy (SMA) is a rare disease but is also the most common fatal genetic disease of infancy. While the approval of the first drug treatment for SMA in 2016 and the FDA approval of the first gene therapy and oral small molecule for SMA have revolutionized SMA management, significant delays in diagnosis and treatment initiation have been observed. This is due to clinicians having limited knowledge regarding SMA diagnostic tests and assessments as well as the latest clinical evidence on approved and emerging therapies, which often contributes to poor outcomes.
This enduring material focuses on implementing evidence-based strategies for diagnosing SMA, applying the latest clinical evidence of approved and emerging therapies, and recognizing individual patient- and parent-/caregiver-related factors that guide clinical decision-making, in order to facilitate access to therapies for SMA management.
At the end of this CE activity, participants should be able to:
- Determine the tests and clinical assessments that can aid in diagnosing SMA as well as monitoring disease activity and treatment response.
- Apply the latest clinical evidence to evaluate the cost-effectiveness of approved and emerging therapies for SMA.
- Recognize the individual patient- and parent-/caregiver-related factors that guide clinical decision-making in SMA management.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Determine the tests and clinical assessments that can aid in diagnosing SMA as well as monitoring disease activity and treatment response.
- Summarize the latest clinical evidence to evaluate the cost-effectiveness of approved and emerging therapies for SMA.
- Recognize the individual patient- and parent-/caregiver-related factors that guide clinical decision-making in SMA management.
Supported by an educational grant from Biogen MA, Inc.
Managed care medical directors/physicians and specialty and managed care pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Enduring: 0376-0000-21-061-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format:
Enduring material
ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Proud reports that she receives research support from AveXis/Novartis Pharmaceuticals Corporation and Biogen. She is on the speakers bureau for AveXis/Novartis Pharmaceuticals Corporation and Biogen. She is a consultant for AveXis/Novartis Pharmaceuticals Corporation; Biogen; and Genentech, Inc./Roche.
Dr. Neil has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report..
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-113-041621-29
